Subscribe
Pet Health & Wellness
6 min read

Alexandru Bacita | Co-Founder & COO, The Cat Health Company

Cats are living longer, but the drugs for age-related disease have not kept pace. The Cat Health Company, a clinical-stage biotech, has three drugs in trials and 11 more preclinical candidates, and has out-licensed its first therapeutic. Co-founder and COO Alexandru Bacita explains why cats compress the drug-development loop, how the company targets muscle loss and kidney disease first, and why the route to longevity runs through veterinarians and pharma partners.

Written by
Roy Ben-Tzvi
Published on
October 27, 2026
Alexandru Bacita, Co-Founder & COO of The Cat Health Company

Cats are living longer, but many age-related diseases still have limited treatment options. The Cat Health Company thinks that can change.

We spoke with Alexandru Bacita, co-founder and COO of The Cat Health Company, a clinical-stage biotech using machine learning to develop medicines for age-related diseases in cats. Bacita previously worked in human drug discovery before turning his attention to feline health.

In less than two years, the company says it has moved three drugs into clinical trials, built a pipeline of 11 more preclinical candidates, and out-licensed its first therapeutic. Its most advanced programs target age-related muscle loss and chronic kidney disease.

But the ambition goes beyond cats. Because cats naturally develop many of the same diseases of aging seen across mammals, the company believes what it learns could eventually help answer a much bigger question: how far can we extend healthy life?

Give us a short intro. What is The Cat Health Company, and what are you ultimately trying to accomplish?

We’re a clinical-stage biotech using machine learning to develop medicines for the diseases of old age in cats. In under two years, we’ve produced clinical-stage drugs, seen treatments make a real difference in very sick cats, and out-licensed our first therapeutic to pharma. Ultimately, we want to go beyond nine lives and then, beyond known limits for all species.

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

Pro
Keep Reading

Other Interviews

More conversations with founders, operators, and investors building the future of pet care.

Learn more
Deven Vespi | Advisor, DRV Advisory
Pet Health & Wellness
13 min read

Deven Vespi | Advisor, DRV Advisory

Clinically proven has no shared definition in pet, yet it now shapes deals as much as labels. Deven Vespi learned the trade in FDA-regulated animal health, and she explains how to check a study before you trust it or build a deal on it. She covers sample sizes, dosing gaps, why brands get blindsided by their own research, and how long published data stays an edge.

Learn more
Learn more
Meet the Founders: 3 Startups Shaping the Future of Pet Health
Pet Health & Wellness
10 min read

Meet the Founders: 3 Startups Shaping the Future of Pet Health

Pawsible Ventures took seven of more than 130 applicants into its second cohort. Three of them work very different corners of pet health. Nicole Shlomof and Gila Leibovitch of Pawp Water sell functional water to owners who already fill the bowl, Andria Beal of EpiPaws turned dolphin epigenetics research into biological-age tests for dogs and cats, and Elliot Greenwood of ChckVet sells software to vet practices that resist new tech.

Learn more
Learn more
Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics
Pet Health & Wellness
17 min read

Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics

Elizabeth Iorns lost her French Bulldog to a brain tumor that a published canine study suggested could be treated, but no company had taken the drug forward for dogs. Now she and Science Exchange co-founder Dan Knox license the companion animal rights to human drugs at Familiar Therapeutics: 13 programs and $5 million raised in five months, plus a pitch to pharma that pet trials validate targets faster than phase two.

Learn more
View all interviews